A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
Public ClinicalTrials.gov record NCT07221188. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)
Study identification
- NCT ID
- NCT07221188
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,250 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 11, 2025
- Primary completion
- Mar 23, 2028
- Completion
- Mar 23, 2028
- Last update posted
- Apr 15, 2026
2025 – 2028
United States locations
- U.S. sites
- 43
- U.S. states
- 12
- U.S. cities
- 37
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Arcadia | California | 91006 | Recruiting |
| GSK Investigational Site | Covina | California | 91723 | Recruiting |
| GSK Investigational Site | Los Angeles | California | 90057 | Recruiting |
| GSK Investigational Site | Santa Maria | California | 93458 | Recruiting |
| GSK Investigational Site | Cape Coral | Florida | 33914 | Recruiting |
| GSK Investigational Site | Doral | Florida | 33016 | Recruiting |
| GSK Investigational Site | Hialeah | Florida | 33016 | Recruiting |
| GSK Investigational Site | Inverness | Florida | 34452 | Recruiting |
| GSK Investigational Site | Jacksonville | Florida | 32216 | Recruiting |
| GSK Investigational Site | Kissimmee | Florida | 34744 | Recruiting |
| GSK Investigational Site | Lakeland | Florida | 33803 | Recruiting |
| GSK Investigational Site | Maitland | Florida | 32751 | Recruiting |
| GSK Investigational Site | Miami | Florida | 33135 | Recruiting |
| GSK Investigational Site | Miami | Florida | 33155 | Recruiting |
| GSK Investigational Site | Miami | Florida | 33156 | Recruiting |
| GSK Investigational Site | Miami | Florida | 33184 | Recruiting |
| GSK Investigational Site | Miami Lakes | Florida | 33014 | Recruiting |
| GSK Investigational Site | Ocala | Florida | 34471 | Recruiting |
| GSK Investigational Site | Palmetto Bay | Florida | 33157 | Recruiting |
| GSK Investigational Site | Topeka | Kansas | 66606 | Recruiting |
| GSK Investigational Site | Springfield | Missouri | 62703 | Recruiting |
| GSK Investigational Site | St Louis | Missouri | 63141 | Recruiting |
| GSK Investigational Site | Jersey City | New Jersey | 07059 | Recruiting |
| GSK Investigational Site | East Syracuse | New York | 13057 | Recruiting |
| GSK Investigational Site | New York | New York | 10036 | Recruiting |
| GSK Investigational Site | Morehead City | North Carolina | 28557 | Recruiting |
| GSK Investigational Site | Akron | Ohio | 44320 | Recruiting |
| GSK Investigational Site | Springboro | Ohio | 45066 | Recruiting |
| GSK Investigational Site | Austin | Texas | 78745 | Recruiting |
| GSK Investigational Site | Austin | Texas | 78759 | Recruiting |
| GSK Investigational Site | Brownsville | Texas | 78526 | Recruiting |
| GSK Investigational Site | Dallas | Texas | 75243 | Recruiting |
| GSK Investigational Site | DeSoto | Texas | 75115 | Recruiting |
| GSK Investigational Site | Richmond | Texas | 77406 | Recruiting |
| GSK Investigational Site | San Antonio | Texas | 78215 | Recruiting |
| GSK Investigational Site | San Antonio | Texas | 78229 | Recruiting |
| GSK Investigational Site | Seabrook | Texas | 77586 | Recruiting |
| GSK Investigational Site | Tomball | Texas | 77375 | Recruiting |
| GSK Investigational Site | Waco | Texas | 76710 | Recruiting |
| GSK Investigational Site | Waco | Texas | 76712 | Recruiting |
| GSK Investigational Site | West Jordan | Utah | 84088 | Recruiting |
| GSK Investigational Site | Manassas | Virginia | 20110 | Recruiting |
| GSK Investigational Site | Seattle | Washington | 98105 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Non-alcoholic Fatty Liver Disease trials
Other public records listing Non-alcoholic Fatty Liver Disease. Sorted by last update posted; newest first. Not a recommendation.
- NCT06005012: Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM Active, not recruiting
- NCT07403604: Effect of Insulin Lowering on Lipogenesis Recruiting
- NCT05583344: Phase 2b Study of GSK4532990 in Adults With NASH Active, not recruiting
- NCT04951219: A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) Active, not recruiting
- NCT03884075: Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) Recruiting
- NCT07221227: A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07221188, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 15, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07221188 live on ClinicalTrials.gov.